Fly News Breaks for March 3, 2020
Mar 3, 2020 | 14:25 EDT
Raymond James analyst Dane Leone upgraded Ocular Therapeutix to Strong Buy from Outperform with a price target of $15, up from $7, after the company presented first data from the OTX-TKI program of hydrogel axitinib for the treatment of wet age-related macular degeneration, or wAMD. He now views OTX-TKI as potentially the highest value asset within the company's emerging pipeline, Leone tells investors.
News For OCUL From the Last 2 Days
There are no results for your query OCUL